Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) will be releasing its earnings data before the market opens on Monday, November 13th. Analysts expect Aldeyra Therapeutics to post earnings of ($0.41) per share for the quarter.
Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.02. On average, analysts expect Aldeyra Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Aldeyra Therapeutics, Inc. (NASDAQ ALDX) opened at $6.20 on Monday. Aldeyra Therapeutics, Inc. has a 52 week low of $3.80 and a 52 week high of $11.90. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.48 and a current ratio of 12.48.
In related news, major shareholder Life Sciences Maste Perceptive acquired 200,000 shares of Aldeyra Therapeutics stock in a transaction on Tuesday, September 19th. The stock was acquired at an average price of $7.25 per share, for a total transaction of $1,450,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 28.40% of the company’s stock.
A hedge fund recently raised its stake in Aldeyra Therapeutics stock. Vanguard Group Inc. lifted its holdings in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) by 3.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 304,633 shares of the biotechnology company’s stock after purchasing an additional 9,407 shares during the period. Vanguard Group Inc. owned about 4.88% of Aldeyra Therapeutics worth $1,431,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 40.25% of the company’s stock.
A number of equities analysts have weighed in on ALDX shares. ValuEngine lowered Aldeyra Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 6th. Cowen and Company reiterated an “outperform” rating and set a $14.00 price objective (up previously from $9.00) on shares of Aldeyra Therapeutics in a research note on Thursday, September 14th. Cantor Fitzgerald started coverage on Aldeyra Therapeutics in a research note on Tuesday, October 24th. They set an “overweight” rating and a $22.00 price objective for the company. Canaccord Genuity reiterated a “buy” rating and set a $27.00 price objective (up previously from $12.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, September 13th. Finally, Zacks Investment Research lowered Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $16.96.
ILLEGAL ACTIVITY WARNING: This report was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2017/11/06/aldeyra-therapeutics-inc-aldx-scheduled-to-post-earnings-on-monday.html.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
What are top analysts saying about Aldeyra Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aldeyra Therapeutics Inc. and related companies.